Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Biol Psychiatry. 2013 Oct 4;76(1):8–14. doi: 10.1016/j.biopsych.2013.09.028

Figure 4. Effect of SCH-23390 on motivation for cocaine following ShA versus ExA self-administration in the vulnerable versus the resistant group.

Figure 4

Mean (± SEM) number of infusions obtained in (A) ShA controls, (B) ExA Resistant, and (C) ExA Vulnerable rats on the day of treatment with SCH-23390 (0, 0.3, 1.0, and 3.0 μg; filled bars) as compared to the pre-treatment baseline (open bars) for each dose. Dashed line indicates average pre-treatment baseline. Arrow with asterisk indicates significant difference in number of infusions obtained averaged across the pre-treament baseline. *Significant difference from pre-treatment baseline. ShA, N=9–11; ExA resistant, N=7–8; ExA vulnerable, N=6–8 for each dose of SCH-23390.